Edwards-JenaValve sets US precedent on pre-commercial markets, grounds for challenge
A decision by a Washington, DC, federal judge that effectively killed Edwards Lifesciences’ proposed acquisition of JenaValve Technology sets an important precedent that harm can be found in markets before product...To view the full article, register now.
Already a subscriber? Click here to view full article